Investigational drug · Phase 2
of TQH2722
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sinusitis, Chronic Rhinosinusitis.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
7
Any phase or sponsor naming "of TQH2722"
First trial start
2023
Dec 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "of TQH2722", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sinusitis
- Chronic Rhinosinusitis
Largest trials
Live from ClinicalTrials.gov: studies naming "of TQH2722" as an intervention, largest first.
- To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06552520 · 500 participants · Start Oct 8, 2024 · Primary completion Sep 11, 2025
Drug: TQH2722 injection; Placebo of TQH2722 injection · For: Atopic Dermatitis
Sites: Bengbu, China; Tongling, China; Wuhu, China · 73 sites in all
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic RhinitisRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07398859 · 300 participants (planned) · Start Mar 19, 2026 · Primary completion Nov 2026
Drug: TQH2722 injection · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Chongqing, China; Baoding, China · 30 sites in all
- Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic RhinitisPivotal-lookingCompleted
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06760182 · 169 participants · Start Mar 10, 2025 · Primary completion Apr 30, 2025
Drug: TQH2722 injection; TQH2722 Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Lanzhou, China; Cangzhou, China · 30 sites in all
- A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.Pivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06089278 · 160 participants · Start Dec 28, 2023 · Primary completion Mar 30, 2025
Drug: 300mg of TQH2722 injection; 600mg of TQH2722 injection and 1 more · For: Sinusitis
Sites: Wuhu, China; Beijing, China; Lanzhou, China · 36 sites in all
- A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic DermatitisPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05970432 · 160 participants (planned) · Start Jun 19, 2023 · Primary completion Mar 2024
Drug: TQH2722 injection 300mg-150mg; TQH2722 injection 600mg-300mg and 2 more · For: Atopic Dermatitis
Sites: Wuhu, China; Guangzhou, China; Shenzhen, China · 32 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06439381 · 119 participants · Start Jul 16, 2024 · Primary completion Dec 19, 2025
Drug: 300mg/600mg of TQH2722 injection · For: Chronic Rhinosinusitis
Sites: Beijing, China; Foshan, China; Shenzhen, China · 27 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05409326 · 48 participants (planned) · Start Jun 2022 · Primary completion Jun 2023
Drug: TQH2722 injection; Placebo to match TQH2722 · For: Atopic Dermatitis
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.